The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Moxonidine (Primary) ; Irbesartan
- Indications Hypertension
- Focus Biomarker; Therapeutic Use
- 01 Feb 2012 Planned number of patients (100) added as reported by ClinicalTrials.gov.
- 01 Feb 2012 Planned End Date (1 Jan 2014) added as reported by ClinicalTrials.gov.
- 01 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.